Form 4: Quest Diagnostics SVP Acquires Shares Under 10b5-1 Plan

Karthik Kuppusamy, SVP of Clinical Solutions at Quest Diagnostics, reported the acquisition of 15 shares of common stock through a dividend reinvestment plan.

Summary

• Karthik Kuppusamy, SVP, Clinical Solutions at Quest Diagnostics Inc. (DGX), filed a Form 4 statement of changes in beneficial ownership.
• The filing reports the acquisition of 15 shares of common stock on October 21, 2025, at a price of $189.076 per share.
• These shares were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and were eligible for deferred reporting on Form 5, but were reported early on this Form 4.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
• Following this transaction, Kuppusamy beneficially owns 8,379 shares directly, 358 shares indirectly through a trust, and 1,635 shares indirectly through a 401(k) plan.
• The direct ownership amount includes exempt purchases made under the company's stock purchase plan since the date of the reporting person's last Form 4 filing.
• The 401(k) shares were acquired on a periodic basis by the trustee of the Company's tax-qualified Profit Sharing (401(k)) Plan.

Sentiment

Score: 6

Explanation: Slightly positive due to an officer acquiring shares, even a small amount, under a 10b5-1 plan, which indicates planned confidence. However, the small quantity limits the overall positive impact and suggests it's a routine, rather than a highly significant, event.

Positives

• An officer acquiring shares, even a small amount, can be viewed as a minor signal of confidence in the company's future prospects.
• The transaction was executed under a Rule 10b5-1 plan, indicating a pre-planned and systematic approach to share acquisition.

Negatives

• The number of shares acquired (15) is relatively small, which limits the significance of this transaction as a strong bullish indicator.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This insider transaction filing is specific to an individual officer's share ownership and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: May interpret the officer's acquisition as a minor positive signal of management's confidence in the company's stock, though the small volume limits its overall impact.

Key Dates

Recommendation

The acquisition of a very small number of shares by an officer, even under a 10b5-1 plan, is not a material event that would warrant a change in investment recommendation. It reflects a routine, pre-planned transaction rather than a significant new conviction or market-moving event.

Keywords

Quest Diagnostics, DGX, Karthik Kuppusamy, Insider Trading, Form 4, Stock Acquisition, Dividend Reinvestment Plan, Officer Transaction, 10b5-1 Plan